Story · Medicine & Biotech · Nutrition

Projected Health and Economic Effects of Expanded Access to Anti-Obesity Medications in Medicare

1 outlet · first reported by medRxiv (all subjects) 15d ago

Coverage, in order

  1. 15d ago
    medRxiv (all subjects) obscure study
    Projected Health and Economic Effects of Expanded Access to Anti-Obesity Medications in Medicare

    Background: The CMS GLP-1 Bridge demonstration (July 2026-December 2027) expands access to GLP-1s for additional eligible Medicare Part D beneficiaries for a $50 monthly copay. Its long-run value depends on uptake, discontinuation, and which beneficiaries initiate therapy, in addition to policy…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.